Watson's Impressive Prelim Results - Analyst Blog


Shutterstock photo

Watson Pharmaceuticals Inc. ( WPI ) recently announced its preliminary results for the financial year 2011.

The company reported preliminary non-GAAP earnings of $4.75 - $4.77 per share, reflecting an increase of 39% over the year-ago figure and well above the Zacks Consensus Estimate of $4.62.

Sales from a generic version of Pfizer 's ( PFE ) cholesterol drug Lipitor contributed 64 cents to the earnings.

Watson Pharma reported preliminary revenues of $4.57 billion, up 28%. The figure is in line with the company's forecast and the Zacks Consensus Estimate of $4.5 billion.

Watson Pharma records revenues under three heads - Global Generics, Global Brands and Distribution. The company said Global Generics revenue amounted to $3.36 billion, driven by the launch of generic versions of Lipitor and Johnson & Johnson 's ( JNJ ) attention-deficit hyperactivity disorder (ADHD) drug Concerta. The company's modified-release and oral contraceptive franchises continued to perform well. Generics revenue was almost in-line with Watson Pharma's guidance.

The company said that Global Brands revenues came in at $440 million, slightly below the company's forecast of $445 million. The branded segment benefited from the growth of the Rapaflo, Gelnique, Crinone and Androderm franchises.

Distribution segment revenues were $776 million, in line with the company's guidance. The segment continued to be affected by a lower number of new product launches by third-parties.


For 2012, Watson Pharma expects to post earnings of $5.25 - $5.55 per share on revenues of about $5.3 billion. The 2012 Zacks Consensus Estimate for revenues is the same as the company, while the earnings estimate lies above the company's range at $5.77 per share.

Watson Pharma expects to report Global Generics revenues in the range of $3.8 - $4.0 billion in 2012. Global Brand revenues are forecasted to be around $500 - $525 million and Distribution segment revenues are expected to lie between $850 and $900 million.

The company expects 2013 non-GAAP earnings to increase about 10% from 2012 levels.

JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
WATSON PHARMA ( WPI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: JNJ , PFE , WPI

More from Zacks.com




Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com